A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer
Background In clinical practice, patients with non-small cell lung cancer (NSCLC) often receive low-dose programmed death-1 (PD-1) monoclonal antibodies due to physical or financial limitations. However, the efficacy and safety of low-dose compared with standard-dose PD-1 monoclonal antibodies remai...
Na minha lista:
| Principais autores: | , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BMJ Publishing Group
2025-06-01
|
| coleção: | Journal for ImmunoTherapy of Cancer |
| Acesso em linha: | https://jitc.bmj.com/content/13/6/e011622.full |
| Tags: |
Sem tags, seja o primeiro a adicionar uma tag!
|